Results - Announcements
Valiant Laboratories Ltd share price declined by 1.49% to Rs 126.0 after the company's net profit plunged by 98.06% to Rs 0.41 crore, while revenue from operations improved marginally 1.28% to Rs 116.77 crore in Q3FY26 over Q2FY26.
The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 27.72 lakh crore, rising 4.75%. It has inched up 2.16% over last one week and gained upto 0.86% in last one month while the market capitalization of Valiant Laboratories Ltd has marginally improved by 1.45% and 104.05% in the same period respectively.
Profit before tax (PBT) of Valiant Laboratories Ltd stood at Rs 0.67 crore in Q3 FY26, jumping 139.29% year-on-year, and crashing by 97.44% quarter-on-quarter. EBITDA came in at Rs 5 crore, tanking 740.51% YoY and nosediving by 82.18% sequentially.
Total expenses soared by 29.67% to Rs 115.26 crore in Q3FY26 over Q3FY25. During the quarter, cost of materials consumed stood at Rs 89.65 crore, witnessing a sharp rise of 43.79% YoY, while employee benefits expense was at Rs 2.93 crore, soaring 12.69% YoY.
For the TTM ended FY26, revenue from operations surged 78.04% to Rs 237.47 crore, while net profit saw a strong growth of 48.64% to Rs 3.27 crore, compared to previous TTM. EBITDA tanked by 716% to Rs 4.07 crore, and PBT collapsed by 150.99% to Rs 0.77 crore compared to previous TTM.
The company's consolidated net cash flow from operating activities stood at Rs 10.43 crore in FY26, as against Rs 1.31 crore in FY25.
Valiant Laboratories Ltd jumped 57.50% in last one year, significantly outperforming the benchmark BSE Sensex which has eased by 9.87% during the same period.